Cobra Biomanufacturing and Auxilium Pharmaceuticals have announced an important contract to produce further cGMP batches and three BLA (Biologics Licence Application) batches of AA4500
This work will complete by calendar year end 2006 and, during this period, Cobra Biomanufacturing and Auxilium Pharmaceuticals will be discussing the terms of a non-exclusive long-term manufacturing agreement for the commercial supply requirements of AA4500.
David Thatcher, chief executive of Cobra Biomanufacturing, commented: "This contract represents an important step in Cobra's evolution from a supplier of early stage clinical trials materials into a supplier of commercial quantities of licensed products.
"Cobra's current contracted forward order book is now £8.6m of which £5.4m is deliverable in the current financial year."
